Busulfan and cyclophosphamide as a conditioning regimen for pediatric acute lymphoblastic leukemia patients undergoing bone marrow transplantation
AJ Shah, C Lenarsky, N Kapoor… - Journal of Pediatric …, 2004 - journals.lww.com
Bone marrow transplantation (BMT) has become the standard therapy for children with
relapsed acute lymphoblastic leukemia. The authors report their experience with
histocompatible BMT for 52 children with acute lymphoblastic leukemia conditioned with a
non-total body irradiation (TBI) regimen using busulfan and cyclophosphamide (Bu/Cy). The
efficacy and long-term toxicity of the Bu/Cy regimen were determined. Overall survival was
35%. One-year, 3-year, and 7-year event-free survival rates were 54%, 33%, and 23 …
relapsed acute lymphoblastic leukemia. The authors report their experience with
histocompatible BMT for 52 children with acute lymphoblastic leukemia conditioned with a
non-total body irradiation (TBI) regimen using busulfan and cyclophosphamide (Bu/Cy). The
efficacy and long-term toxicity of the Bu/Cy regimen were determined. Overall survival was
35%. One-year, 3-year, and 7-year event-free survival rates were 54%, 33%, and 23 …
